In the study, treatment of patients with non-small-cell lung cancer with Rocaltrol (active vitamin D3) decreased the expression of PD-1, TIM-3, and TIGIT and resulted in cytokine production associated with anti-tumor immunity. This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.